Rheumatech co-author of paper on the role of PKA in regulating immune sensitivity
August 27, 2017
Rheumatech employee co-author on Dr. Line Victoria Moen's paper: "Ablation of the Cβ2 subunit of PKA in immune cells leads to increased susceptibility to systemic inflammation in mice" in the European Journal of Immunity.
Main findings include characterization of mice ablated for the Cβ2 protein demonstrating a significantly reduced cAMP-induced catalytic activity of PKA in the spleenocytes, lymphocytes and thymocytes and significantly increased numbers of CD62L-expressing CD4+ and CD8+ T cells in LNs accompanied by increased susceptibility to systemic inflammation by the Cβ2 ablated mice.
Rheumatech awarded innovation funds by Horizon 2020 program PERMIDES
August 01, 2017
Rheumatech has been awarded an innovation voucher from the PERMIDES program (Personalized Medicine Innovation through Digital Enterprise Solutions, http://permides.eu/). PERMIDES is one of the five European INNOSUP-1-2015-Cluster facilitated programs for new value chain development projects in healthcare. We have received a voucher of 60 k€ on a project initiating this August. The grant will fund the development of a personalized companion diagnostic tool for rheumatoid arthritis (RA) patients, named PERDIRA (PERsonalized companion DIagnostic for Rheumatoid Arthritis patients). The project is to be carried out by the Norwegian IT/bioinformatics company PubGene (http://www.pubgene.com). PERDIRA will support analysis and exploration of patient metabolite data to predict individual responsiveness to biologicals, DMARDs and/or the drugs targeting metabolism under development by Rheumatech. The goal is to improve RA patient stratification and help achieve an optimal personalized treatment. This will help Rheumatch to improve future clinical trials and enhance drug marketability.
Rheumatech consortium is granted EUR 1.96M from Eureka Eurostars
September 30, 2016
This project aims to advance a first-in-class drug candidate into clinical phase for the treatment of rheumatoid arthritis (RA) and thereby improve quality of life for these patients. Through the Eurostars project we aim to improve our compounds and demonstrate that our candidates are non-toxic by using pre-clinical, in vivo and in vitro toxicity screening. To collect early clinical data a microdialysis platform will be set up for detection of biomarkers and proof-of-principle studies.
Rheumatech employee co-author on Dr. Roman Volchenkov's paper: "Metabolic profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis samples" in the Scandinavian Journal of Rheumatology.
Main findings include data pointing towards an altered metabolism of metabolites glucose and choline in samples from rheumatoid arthritis patients.
Rheumatech entered development cooperation with Drug Discovery Laboratory AS
September 30, 2014
Rheumatech has entered an optimization and development program with drug discovery and development company Drug Discovery Laboratory AS. The program will optimize the potency of identified hit compounds active in inhibiting target proteins in immune cell energy generation and improve pharmacokinetics.
Rheumatech entered development program with Evotec AG
April 30, 2014
Rheumatech has entered a development program with drug discovery and development partnership company Evotec AG. The program will optimize identified hit compounds active in inhibiting target proteins in immune cell energy generation.